Trial reportClinical drug investigation2013
Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients.
Trial report in Clinical drug investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 6 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety.Frontiers in pain research (Lausanne, Switzerland) · 2024Pooled it
- Interventions for itch in people with advanced chronic kidney disease.The Cochrane database of systematic reviews · 2020Pooled it
- Interventions for improving sleep quality in people with chronic kidney disease.The Cochrane database of systematic reviews · 2019Pooled it
- Quality of Life in Painful Peripheral Neuropathies: A Systematic Review.Pain research & management · 2019Pooled it
- Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis.The Cochrane database of systematic reviews · 2016Pooled it
- Abuse Potential of Pregabalin: A Systematic Review.CNS drugs · 2016Pooled it
- Longitudinal associations of depressive symptoms and pain with quality of life in patients receiving chronic hemodialysis.Hemodialysis international. International Symposium on Home Hemodialysis · 2015Trial
- Gabapentin-Associated Movement Disorders: A Literature Review.Medicines (Basel, Switzerland) · 2023Review
- Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients.Journal of the American Society of Nephrology : JASN · 2018Article
- HCN Channel Targets for Novel Antidepressant Treatment.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs.Drugs in R&D · 2016Review
- Update on neuropathic pain treatment: ion channel blockers and gabapentinoids.Current pain and headache reports · 2013Review
- Review of neuropathic pain screening and assessment tools.Current pain and headache reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPainful peripheral neuropathy (PPN) is common in haemodialysis patients and associated with impaired health-related quality of life (HR-QoL). Gabapentin and pregabalin have not been fully investigated in haemodialysis patients. Therefore, we compared the effects of gabapentin and pregabalin on intensity of pain and associated HR-QoL in haemodialysis patients with PPN.
methodsGabapentin and pregabalin were administered after each haemodialysis session at doses of 300 and 75 mg, respectively. Patients were randomized into two groups; after 6 weeks patients underwent a 2-week washout and crossover and received another 6 weeks of treatment. All patients underwent electromyography at the outset. The short-form McGill pain questionnaire (SF-MPQ) for assessment of pain, and short-form medical outcomes study for assessment of HR-QoL at baseline and at the end of the study were applied.
resultsForty patients completed the 14-week study period. Gabapentin and pregabalin significantly improved SF-MPQ total scores compared with pretreatment values (mean ± SD) [from 18.9 ± 4.3 to 9.3 ± 4.3 for gabapentin, p < 0.001, and from 18.5 ± 3.9 to 9.8 ± 3.6 for pregabalin, p < 0.001]. There was no significant difference between the study drugs in terms of efficacy against neuropathic pain (p > 0.05). Both gabapentin and pregabalin significantly improved HR-QoL at the end of the study compared with pretreatment scores (p < 0.001).
conclusionOur results showed strong efficacy of gabapentin and pregabalin on pain intensity in the given doses. HR-QoL was also significantly improved by both drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.